BurstDR™ micrOdosing stimuLation in De-novo Patients (BOLD)

The purpose of this study is to evaluate the therapeutic efficacy of microdosing BurstDR stimulation in spinal cord stimulation (SCS) patients with chronic intractable back and/or leg pain.

Study Overview

• Status: Completed
• Conditions: Pain, Intractable; Pain, Back
• Intervention / Treatment: Device: Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.

Detailed Description

Microdosing BurstDR consists of periods during which stimulation is delivered with standard BurstDR stimulation parameters alternated with periods during which no stimulation is being delivered.

In this study the investigators propose to evaluate therapeutic efficacy of BurstDR microdosing, and determine optimal microdosing programming parameters in chronic pain patients, who are eligible for SCS therapy.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Santa Rosa, California, United States, 95403
      • Thrive Clinic
  • Nevada
    • Reno, Nevada, United States, 89511
      • Nevada Advanced Pain Specialists
  • North Carolina
    • Asheville, North Carolina, United States, 28803
      • OnSite Clinical Solutions
  • Texas
    • Killeen, Texas, United States, 76542
      • Ambulatory Surgery Center of Killeen
  • West Virginia
    • Charleston, West Virginia, United States, 25301
      • Premier Pain Solutions

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is able to provide informed consent to participate in the study;
• Subject diagnosed with chronic intractable pain associated with back and/or limbs;
• Subject is 18 years of age or older;
• Subject has failed to respond to at least 6 months of conventional treatment which may include pharmacological treatment, physical therapy, epidural injections;
• Subject has a back and/or leg pain intensity of at least 6.0 cm out of 10.0 cm on the average back and/or leg pain visual analogue scale at baseline;
• Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
• Subject is on stable pain medications with a total opioid for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose increase until the 3 month visit;
• Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
• Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study

Exclusion Criteria:

Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, post-herpetic neuralgia or uncontrolled diabetes mellitus;

• Subject is currently participating in a clinical investigation that includes an active treatment arm;
• Subject has been implanted with or participated in a trial period for a neurostimulation system;
• Subject has an infusion pump;
• Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
• Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
• Subject is immunocompromised;
• Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
• Subject has history of cancer requiring active treatment in the last 12 months;
• Subject has an existing medical condition that is likely to require the use of diathermy in the future;
• Subject has documented history of allergic response to titanium or silicone;
• Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
• Subject is a female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test);
• Subject has life expectancy of less than 6 months;
• Subject is involved in an injury claim under current litigation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Microdosing group; Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.	Device: Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.; BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation	Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)	baseline and 1 week after trial lead implant (trial stimulation)
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 1	Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)	Baseline and 1 month follow up visit
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 2	Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)	Baseline and 3 month follow up visit
Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 3	Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)	Baseline and 6 month follow up visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Quality of Life Between Baseline and Trial Stimulation	Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)	Baseline and 1 week after trial lead implant (trial stimulation)
Change in Quality of Life Between Baseline and Follow up 1	Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)	Baseline and 1 month follow up visit
Change in Quality of Life Between Baseline and Follow up 2	Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)	Baseline and 3 month follow up visit
Change in Quality of Life Between Baseline and Follow up 3	Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)	Baseline and 6 month follow up visit
Change in Disability Index Between Baseline and Trial Stimulation	questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)	Baseline and 1 week after trial lead implant (trial stimulation)
Change in Disability Index Between Baseline and and Follow up 1	questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)	Baseline and 1 month follow up visit
Change in Disability Index Between Baseline and and Follow up 2	questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)	Baseline and 3 month follow up visit
Change in Disability Index Between Baseline and and Follow up 3	questionnaire on disability (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)	Baseline and 6 month follow up visit
Change in Pain Catastrophizing Scale Between Baseline and Trial Stimulation	Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)	Baseline and 1 week after trial lead implant (trial stimulation)
Change in Pain Catastrophizing Scale Between Baseline and Follow up 1	Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)	Baseline and 1 month follow up visit
Change in Pain Catastrophizing Scale Between Baseline and Follow up 2	Questionnaire on pain catastrophizing (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)	Baseline and 3 month follow up visit
Change in Pain Catastrophizing Scale Between Baseline and Follow up 3	Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)	Baseline and 6 month follow up visit

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stimulation ON/OFF Ratio	Percentage of patients using each ON/OFF ratio	6 month follow up visit

Collaborators and Investigators

• Sponsor: Abbott Medical Devices
• Investigators: Principal Investigator: Timothy R Deer, MD, The Center for Pain Relief

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 30, 2017
• Primary Completion (ACTUAL): July 2, 2019
• Study Completion (ACTUAL): July 2, 2019

Study Registration Dates

• First Submitted: November 10, 2017
• First Submitted That Met QC Criteria: November 20, 2017
• First Posted (ACTUAL): November 22, 2017

Study Record Updates

• Last Update Posted (ACTUAL): March 19, 2020
• Last Update Submitted That Met QC Criteria: March 6, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Back Pain; Pain, Intractable
• Other Study ID Numbers: SJM-CIP-10215

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes